Chong Kun Dang Pharmaceutical Corp
KRX:185750

Watchlist Manager
Chong Kun Dang Pharmaceutical Corp Logo
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Watchlist
Price: 78 800 KRW -1.25% Market Closed
Market Cap: 1.1T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+1%
Revenue
Forecast
+7%
Operating Income
Forecast
+10%
Net Income
Forecast
+5%

Wall Street
Price Targets

Price Targets Summary
Chong Kun Dang Pharmaceutical Corp

Wall Street analysts forecast Chong Kun Dang Pharmaceutical Corp stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chong Kun Dang Pharmaceutical Corp is 123 998.44 KRW with a low forecast of 96 190.49 KRW and a high forecast of 149 100 KRW.

Lowest Forecast
Wall Street Target
96 190.49 KRW
22% Upside
Average Forecast
Wall Street Target
123 998.44 KRW
57% Upside
Highest Forecast
Wall Street Target
149 100 KRW
89% Upside
Lowest
Price Target
96 190.49 KRW
22% Upside
Average
Price Target
123 998.44 KRW
57% Upside
Highest
Price Target
149 100 KRW
89% Upside
Chong Kun Dang Pharmaceutical Corp Competitors:
Price Targets
Z
002332
Zhejiang Xianju Pharmaceutical Co Ltd
65% Upside
SNT
Syntara Ltd
158% Upside
C
1093
CSPC Pharmaceutical Group Ltd
45% Upside
4746
Formosa Laboratories Inc
66% Upside
Z
002332
Zhejiang Xianju Pharmaceutical Co Ltd
65% Upside
SNT
Syntara Ltd
158% Upside
C
1093
CSPC Pharmaceutical Group Ltd
45% Upside
4746
Formosa Laboratories Inc
66% Upside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
47% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
24% Upside
600195
China Animal Husbandry Industry Co Ltd
20% Upside

Revenue
Forecast

Revenue Estimate
Chong Kun Dang Pharmaceutical Corp

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's revenue is 8%. The projected CAGR for the next 3 years is 8%.

8%
Past Growth
8%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Chong Kun Dang Pharmaceutical Corp

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's operating income is 6%. The projected CAGR for the next 3 years is 5%.

6%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Chong Kun Dang Pharmaceutical Corp

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's net income is 13%. The projected CAGR for the next 3 years is -2%.

13%
Past Growth
-2%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Chong Kun Dang Pharmaceutical Corp's stock price target?
Price Target
123 998.44 KRW

According to Wall Street analysts, the average 1-year price target for Chong Kun Dang Pharmaceutical Corp is 123 998.44 KRW with a low forecast of 96 190.49 KRW and a high forecast of 149 100 KRW.

What is Chong Kun Dang Pharmaceutical Corp's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's revenue is 8%. The projected CAGR for the next 3 years is 8%.

What is Chong Kun Dang Pharmaceutical Corp's Operating Income forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's operating income is 6%. The projected CAGR for the next 3 years is 5%.

What is Chong Kun Dang Pharmaceutical Corp's Net Income forecast?
Projected CAGR
-2%

For the last 8 years the compound annual growth rate for Chong Kun Dang Pharmaceutical Corp's net income is 13%. The projected CAGR for the next 3 years is -2%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.